

Stefan H Hohnloser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/14552/publications.pdf>

Version: 2024-02-01

49
papers

20,787
citations

257101

24
h-index

214527

47
g-index

49
all docs

49
docs citations

49
times ranked

17038
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	13.9	7,537
2	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
3	Subclinical Atrial Fibrillation and the Risk of Stroke. <i>New England Journal of Medicine</i> , 2012, 366, 120-129.	13.9	1,751
4	Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. <i>Lancet</i> , 2000, 356, 1789-1794.	6.3	1,100
5	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 377, 1513-1524.	13.9	1,099
6	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372.	1.6	1,035
7	Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2012, 33, 2821-2830.	1.0	491
8	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. <i>European Heart Journal</i> , 2017, 38, 1339-1344.	1.0	428
9	Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 961-970.	1.6	346
10	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2018, 39, 1726-1735a.	1.0	133
11	Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. <i>European Heart Journal</i> , 2019, 40, 3013-3021.	1.0	125
12	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
13	ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). <i>American Heart Journal</i> , 2006, 152, 442-447.	1.2	117
14	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. <i>Circulation</i> , 2014, 130, 94-125.	1.6	102
15	Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etxilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016, 39, 555-564.	0.7	65
16	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. <i>European Heart Journal</i> , 2019, 40, 1553-1562.	1.0	62
17	Incidence of Cardiac Perforation With Conventional and With Leadless Pacemaker Systems: A Systematic Review and Meta-Analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 336-346.	0.8	59
18	Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. <i>Clinical Research in Cardiology</i> , 2017, 106, 618-628.	1.5	56

#	ARTICLE	IF	CITATIONS
19	Rationale and Design of ATHENA: A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 19, 071121154351003-???	0.8	51
20	Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation. <i>Thrombosis and Haemostasis</i> , 2019, 119, 971-980.	1.8	49
21	Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 882-893.	1.8	48
22	Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure. <i>Stroke</i> , 2015, 46, 667-672.	1.0	46
23	Discrimination Between Ventricular and Supraventricular Tachycardia by Dual Chamber Cardioverter Defibrillators: Importance of the Atrial Sensing Function. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 183-190.	0.5	31
24	Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database. <i>Clinical Research in Cardiology</i> , 2019, 108, 1042-1052.	1.5	27
25	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020, 41, 2848-2859.	1.0	25
26	Worldwide Clinical Experience with a Down-Sized Active Can Implantable Cardioverter Defibrillator in 162 Consecutive Patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998, 21, 1778-1783.	0.5	24
27	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 216-226.	1.4	23
28	Age-related regulation and region-specific distribution of ion channel subunits promoting atrial fibrillation in human left and right atria. <i>Europace</i> , 2019, 21, 1261-1269.	0.7	21
29	Usefulness of the WCD in patients with suspected tachycardia. <i>Clinical Research in Cardiology</i> , 2018, 107, 70-75.	1.5	13
30	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. <i>American Heart Journal</i> , 2019, 212, 13-22.	1.2	13
31	Clinical outcomes after implantation of quadripolar compared to bipolar left ventricular leads in patients undergoing cardiac resynchronization therapy: a systematic review and meta-analysis. <i>Europace</i> , 2019, 21, 1543-1549.	0.7	12
32	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	1.2	11
33	An Unusual Cause of ICD Shock. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997, 20, 2265-2267.	0.5	9
34	Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1553-1561.	1.1	9
35	Reexamination of the Embolic Stroke of Undetermined Source Concept. <i>Stroke</i> , 2021, 52, 2715-2722.	1.0	9
36	Efficacy and safety of transvenous lead extraction in 108 consecutive patients: a single-centre experience. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 704-708.	0.5	8

#	ARTICLE	IF	CITATIONS
37	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. <i>Thrombosis and Haemostasis</i> , 2021, 121, 518-528.	1.8	8
38	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. <i>Cardiovascular Research</i> , 2022, 118, 295-304.	1.8	8
39	Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e017155.	1.6	6
40	Effectiveness of singleâ€•vs dualâ€•coil implantable defibrillator leads: An observational analysis from the SIMPLE study. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1078-1085.	0.8	5
41	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCIÂ•Trial. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 768-780.	1.1	5
42	Effects of apixaban compared with warfarin as gain in event-free time â€• a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1311-1319.	0.8	4
43	Autonomic Modulation in Postinfarction Patients with Sustained Ventricular Tachyarrhythmias. <i>Clinical Science</i> , 1996, 91, 141-145.	0.0	3
44	Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. <i>Europace</i> , 2021, 23, 65-72.	0.7	2
45	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after <scp>PCI</scp> in patients with atrial fibrillation (a <scp>REâ€•DUAL) Tj ETQq1 1 0.784314 2gBT /Over Cardiology, 2021, 44, 1002-1010.	0.7	1
46	Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008655.	2.1	1
47	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , 2020, 133, 1302-1312.	0.6	1
48	How to maximize QRS narrowing. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2019, 30, 229-232.	0.3	0
49	Is there a role for verapamil beyond rate control in paroxysmal atrial fibrillation?. <i>Europace</i> , 2021, , .	0.7	0